MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Categories (click each to see list of all clinical trials associated with that category): Leukemia/MDS/MPD (ONC)
Current Status: Open
Phase: N/A (Cancer Control)
Principal Investigator: Haddadin, Michael
Contact Information:
Stephanie Parker
steparker@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT05564390?term=NCT05564390&rank=1#participation-criteria
Summary
PRIMARY OBJIECTIVES:
a. Screening and Reassessment (MSRP): To evaluate the feasibility of MATCHBox organizing all specimen testing results needed for assignment to a myeloMATCH clinical trial or Tier Advancement Pathway (TAP) within one hour prior to the first Treatment Verification Call held 4 days after MDNet receipt of all required specimens for initial therapy and within 11 days for subsequent therapies.
b. Tier Advancement Pathway (TAP): To enable participants who are not matched to an investigational myeloMATCH treatment sub study to receive-standard of care (SOC} while remaining on the MSRP to maintain access to later tiers of treatment substudies.
SECONDARY OBJECTIVES:
a. Screening and Reassessment (MSRP)
1.To describe the time to MDNet generation of all specimen testing results required for treatment substudy (or TAP) assignment, time-to treatment substudy {or TAP) assignment, percent assigned to a myeloMATCH treatment substudy, and the percent of screened participants who register to a myelo MATCH investigational treatment substudy or are assigned to TAP:
a. Separately within each tier of myeloMATCH treatment substudy and analogous TAP assignment (see Section 2.1 for tier definitions)
b. Separately within each clinical basket of myeloMATCH treatment substudies {see Section 2.2 for clinical basket definitions}.
c. Over time, across and within the Categories above.